Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [795]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [795]

Body mass index

anorexia nervosa and , 308

bulimia nervosa and , 313–14

Bonding, as outcome of positive youth development , 503

Bone mineral density, in anorexia nervosa , 280

Borderline personality disorder, plus suicidal behavior, dialectical behavioral therapy for , 477

Brain . See also Neurobiology

abnormalities

in anxiety disorders , 186–87

in children of schizophrenic parents , 153

in mood disorders , 26–27

violence exposure and , 61

circuitry

developmental shifts , xxx–xxxi, 175–76

in schizophrenia , 97–101

development

during adolescence , xxix–xxxi, 85–86 , 87 f, 175–76

myelinization , xxx, 86 , 87 f

synaptic pruning , xxix–xxx, 85–86 , 87 f, 175

executive inhibitory circuitry defects, in substance use disorders , 379–80

imaging

in anxiety disorders , 178–79

in mood disorders , 26–27

in schizophrenia , 86–88

in substance use disorders , 380–84

reward center dysregulation , 337 , 338

allostasis and , 378

animal models , 372–77 , 373 f, 374 f

imaging studies , 380–84

pharmacotherapy for , 402–3

volume

developmental changes , xxx, 85–86 , 87 f, 175

in schizophrenia , 86–88

Brief dynamic therapy, for major depressive disorder , 32

Brief interventions, for substance use , 563

Brief strategic family therapy, for substance use disorders , 395–96

Bulimia nervosa . See also Eating disorders

combination therapy , 294

comorbidity , 273 , 327

diagnostic criteria , 261–63 , 262 t, 326

dieting and , 304 , 317–18

DSM-IV criteria , 261–63 , 262 t

epidemiology , 263–72 , 275 t, 277 t, 326–27

etiology , 258–59

full-syndrome , 268–69

genetics , 314–15

medical complications , 276 t, 278–79 , 327

outcome , 274 , 327

partial-syndrome , 269

pharmacotherapy , 293–94 , 298

prevalence , 263–68 , 269 , 270 , 275 t, 277 t

prevention programs , 319–23

combined , 322

in high-risk populations and settings , 322

research agenda , 332

targeted , 321–22

universal , 319–21

psychosocial therapy , 288–91 , 296–97

relapse prevention , 296–97 , 298 , 329

risk factors , 312–15 , 330–31

Bullying

school professional findings , 602 , 602 t

suicidal behavior and , 440

Buprenorphine, for opioid addiction , 403 , 406

Bupropion

for ADHD plus substance use disorder , 408

for major depressive disorder , 42–43

for smoking cessation , 405

Buspirone, for generalized anxiety disorder , 194–95 , 197

Calcium supplementation, in anorexia nervosa , 279–80

California, reform initiatives on delivery of evidence-based practices , 556–57

Caloric requirements , 258

Cannabis . See Marijuana use

Carbamazepine

for bipolar disorder

in adolescents , 52 , 52 t

in adults , 50

for post-traumatic stress disorder , 213

Cardiovascular system

in anxiety disorders , 177–78 , 223–24

in eating disorders , 276 t

Caring School Community , 516 t

CASASTART (Striving Together to Achieve Rewarding Tomorrows), 577

Case identification, in mental health disorders , 57–58 , 66

CASEL (2003), 518 t

Catatonic features, depression with , 6

Catchment approach, for prevention of substance abuse , 426

Catechol-O-methyl transferase (COMT), as schizophrenia susceptibility gene , 104 , 105

CBT . See Cognitive-behavioral therapy

Center for Mental Health Services System of Care , 556–57

Center for Prevention Research , 57

Central intake unit, for substance abuse treatment , 575–76

Cerebellum, developmental changes , xxvii, 175–76

end p.795